Immunity Against a Japanese Local Strain of Porcine Reproductive and Respiratory Syndrome Virus Decreases Viremia and Symptoms of a Highly Pathogenic Strain

HIROSHI ISEKI (✉ hiseki@affrc.go.jp)
National Institute of Animal Health, NARO  https://orcid.org/0000-0002-1727-058X

Kenji Kawashima
National Institute of Animal Health, NARO

Tomoyuki Shibahara
National Institute of Animal Health, NARO

Masaji Mase
National Institute of Animal Health, NARO

Research article

Keywords: cross-protection, highly pathogenic, immunity, pathogenicity, pig, porcine reproductive and respiratory syndrome virus, PRRS, vaccine

DOI: https://doi.org/10.21203/rs.3.rs-219725/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** The type 2 highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) has spread throughout countries of southeast Asia, where it has caused severe economic losses. Even countries presently free of PRRSV are at high risk for infection and spread of this virus. Some of these countries, including Japan, have broad epidemics of the local type 2 PRRSV, creating chronic pathogenicity in the domestic pig population. The present study aimed to evaluate the protective efficacy of immunity by infection with a Japanese field isolate, EDRD1, against heterologous challenge with a Vietnamese HP-PRRSV field strain. To this end, four groups of PRRSV-negative crossbreed piglets were used for a challenge study. Groups 1 and 2 were inoculated with EDRD1 via the intranasal route. After 26 days, Groups 2 and 3 were inoculated with HP-PRRSV via the same route. Group 4 served as an uninfected control. Blood and oral fluid samples were taken every 3–4 days after HP-PRRSV challenge; on day 16 post-challenge, all pigs were euthanized, and examined pathologically.

**Results:** The nucleotide sequence analysis of nonstructural protein 2 gene of EDRD1 and comparison with Vietnamese HP-PRRSV showed that the 39 amino acid deletion sites of EDRD1 was nearly in the same region as the 29 amino acid deletion sites of HP-PRRSV. Immunity conferred by inoculation with EDRD1 dramatically reduced viral load in the sera and tissues besides viral shedding (Group 2) compared with those in pigs infected only with HP-PRRSV (Group 3). The clinical signs and rectal temperature were significantly reduced, and the average daily weight gain was significantly improved in the EDRD1-inoculated pigs (Group 2) compared with the Group 3 pigs. Notably, no viral RNA was detected in various organs of the Group 2 pigs 16 days post-infection with HP-PRRSV, except in one pig. Therefore, the immunity induced by EDRD1 and its genetically close field isolates may play a role in reducing viremia caused by HP-PRRSV.

**Conclusions:** The results of the present study demonstrate that pigs are highly protected against heterologous Vietnamese HP-PRRSV challenge by immunity against a Japanese local strain, EDRD1.

**Background**

Porcine reproductive and respiratory syndrome (PRRS) is characterized by reproductive failure in sows and respiratory symptoms in piglets and growing pigs. The etiologic agent of PRRS is the PRRS virus (PRRSV), an enveloped, single-stranded, positive-sense RNA virus, which belongs to the newly classified genus *Rodartevirus* in the family *Arteriviridae* in the order Nidovirales [1]. PRRSV was first reported in Europe during 1990 [2] and in the United States during 1992 [3]. Two distinct genotypes of PRRSV, which share approximately 60% identity at the nucleotide level, have been described: type 1 (European genotype) and type 2 (North American genotype) [4]. Although PRRSV was generally defined as the etiologic agent of chronic infection in pigs, a recently identified highly pathogenic PRRSV (HP-PRRSV) causing high fever and mortality in animals of all ages has emerged from both types 1 and 2 [5, 6]. The type 2 HP-PRRSV isolated in China in 2006 shows a unique discontinuous 30 amino acid deletion in the nonstructural protein 2 (nsp2) gene in open reading frame (ORF) 1a [5, 7]. The virus and its evolved
variants have rapidly spread throughout countries of southeast Asia, where it has caused severe economic losses [8, 9]. Countries presently free from this highly virulent PRRSV, such as Japan, remain at high risk for the invasion and spread of this virus.

In Japan, type 2 non-HP-PRRSV infection was first described in 1994 [10, 11]. Since then, although various type 2 PRRSV variants classified to some of the different lineages based on the ORF5 gene analysis has been detected all over the country [12]. Interestingly, we found that the standard strain in Japan, EDRD1, has a 39 amino acid deletion, which is in almost the same region as the nsp2 gene with the HP-PRRSV in the present study. Nsp2, a region of the ORF1 replicase protein, is highly heterogeneous and has various deletions and insertions [13]. Although the size of nsp2 is variable because of hypervariability in the central region, suggesting the existence of a nonessential region for replication in nsp2 [14], how this may affect cross-protection between PRRSVs remains unclear. However, Leng and his colleagues [15] reported that the nsp2 region of an attenuated strain of Chinese HP-PRRSV played a key role in the induction of neutralizing antibodies in piglets. Reports have described the difficulty in predicting the strength of protective immunity against PRRSV infections among heterogeneous viral strains by analyzing contributing factors, such as the production of neutralizing antibodies [16] and genetic characteristics [17]. Therefore, the evaluation of the cross-immunity between PRRSVs might depend upon challenge studies of whether a vaccine can alleviate pathological conditions. To date, no reports have evaluated the protective immunity derived from infection with uniquely evolved viruses in Japan against the HP-PRRSV. The present study aimed to determine the cross-protection of a Japanese local strain, EDRD1, against heterologous type 2 HP-PRRSV challenge with a low-passage Vietnamese HP-PRRSV field isolate (strain 10186-614) in growing pigs by evaluation of the clinical symptoms, growth parameters, viral replication, and development of antibodies against PRRSV.

Results

Comparative analysis of the nsp2 and ORF5 genes

To evaluate the similarity of the deletion site in the nsp2 gene between EDRD1 and HP-PRRSV (strain 10186-614), we conducted comparisons of these with two other reference strains, namely, VR-2332 and JXA1. An amino acid alignment of the partial sequences of nsp2 in these four strains, in order of their pairwise identity, is shown in Figure 1. Strain 10186-614 contained two discontinuous deletions in the translated protein with deletion sizes of 1 and 29 amino acids corresponding with amino acid positions at 482 and 538–567, respectively, in VR-2332 nsp2. By contrast, EDRD1 contained one continuous deletion of 39 amino acids corresponding with amino acid positions 509–547 in VR-2332 nsp2. Two potential N-glycosylation sites were detected in VR-2332 and EDRD1 at amino acid positions 325 and 697 of VR-2332 nsp2. However, amino acid position 325 is a commonly mutated asparagine-to-lysine residue in JXA1 and 10186-614 strains. The conserved cysteine residue proposed to interact with the matrix protein and the protease sequence that is conserved within PRRSV and equine arteritis virus were well conserved among all four strains.
ORF5 encodes glycoprotein (GP) 5, which is frequently used for the diagnostic identification of PRRSV [18]. To elucidate the genetic distances between 10186-614 and EDRD1, we aligned GP5 among the four strains (Table 1). Alignment of PRRSV GP5 determined shared amino acid identities ranging from 87.9% to 89.5% between VR-2332 and other strains and from 88.9% to 89.9% between EDRD1 and other strains. Additionally, strains 10186-614 and JXA1 shared 97.0% identity.

Clinical signs

Clinical scores in the EDRD1-inoculated group (Group 2) were significantly lower than those in the group without EDRD1 inoculation (Group 3) from 3 days post-infection (dpi) till the end of the experiment with strain 10186-614 (Fig. 2A). After 10186-614 challenge, pigs in Group 3 exhibited periocular edema and redness of the skin on the trunk. These pigs demonstrated a poor appetite and respiratory signs and became seriously ill with coughing and abdominal breathing. These clinical signs persisted through the end of the experiment. A proportion of the animals in Group 3 lay collapsed in the recumbent position and exhibited intermittent thrill. One of these (pig G17) was euthanized on 12 dpi due to difficulty drinking water by itself. By contrast, three of five pigs in Group 2 transiently showed loss of appetite and tachypnea between 3 and 12 dpi, but the pigs recovered by 13 dpi. No clinical signs were observed in animals not challenged with strain 10186-614 (Groups 1 and 4).

Daily weight gain and rectal temperature

The mean daily weight gain of the pigs in Group 3 was significantly lower than that of Group 2 between 9 and 13 dpi (Fig. 2B). By the day of necropsy (16 dpi), the mean weight gain was 9.00 kg for Group 1 (EDRD1 inoculation without HP-PRRSV challenge), 10.00 kg for Group 2 (EDRD1 inoculation and HP-PRRSV challenge), 5.13 kg for Group 3 (HP-PRRSV challenge without EDRD1 inoculation), and 9.60 kg for Group 4 (uninfected controls).

The mean rectal temperature in two of five pigs (pig G9 and G12) in Group 2 increased transiently at 3 dpi, whereas that of all animals of Group 3 rapidly increased until plateauing 3 dpi (Fig. 2C). Overall, by 5 dpi and afterward, the mean rectal temperatures in Group 3 were significantly higher than those in Group 2. No significant difference arose in the mean rectal temperatures between Groups 1, 2, and 4.

Antibody to PRRSV

Antibodies against PRRSV were observed in Groups 1 and 2 beginning at 7 days after EDRD1 inoculation in some pigs and were over the cutoff line (sample-to-positive ratio, S/P, 0.4) in all animals at 11 days after EDRD1 inoculation (~15 dpi of the challenge) (Fig. 3). Although the S/P ratio of four of five pigs in Group 2 was 1.28, 1.24, 1.37, and 1.32, that of pig G12 was 0.63 at 11 days after EDRD1 inoculation. The S/P ratio of G12 then gradually rose very slowly compared with those of the other four pigs, and that of
pig G12 was 0.92 at 0 dpi. In Group 3, the positive conversion of antibody to PRRSV was observed at 7 or 10 dpi, and the S/P ratio of viral antibody gradually rose. By contrast, no antibodies against PRRSV were observed in uninoculated Group 4.

**Viral RNA**

Serum viral load (viral RNA copies/mL) in Group 3 was significantly higher than that of Group 2 at 3 and 13 dpi (Fig. 4A). The mean 10186-614 viral RNA in Group 3 pigs sharply rose at 3 and 7 dpi and plateaued afterward between $2.8 \times 10^6$ and $4.9 \times 10^6$ copies/mL. By contrast, the viral load in two of five pigs in Group 2 transiently rose at 7 dpi (pig G9) and 7 and 10 dpi (pig G7) and in a third pig reached $5.3 \times 10^3$ to $2.9 \times 10^4$ copies/mL from 7 to 13 dpi (pig G12). For the remaining two pigs in Group 2, viral RNA in both sera and oral fluid remained under the detection limit (pigs G8 and G10) after 10186-614 challenge. Viral RNA was detected in oral fluid from all animals in Group 3 at 7, 10, and 13 dpi (Fig. 4B). The viral load in the oral fluid in Group 2 was transiently detected in pigs G7 and G9 at 7 dpi and was intermittently detected in pig G12 at 7, 10, and 13 dpi. At necropsy on 16 dpi, viral RNA was detected in all tested organs, namely, the lung, liver, tonsil, kidney, spleen, and brain of all pigs inoculated with 10186-614 in Group 3 (Fig. 5A). Mean viral RNA copies/g tissue were approximately $5.2 \times 10^6$ in the lung, $2.2 \times 10^5$ in the liver, $1.3 \times 10^7$ in the tonsil, $2.6 \times 10^5$ in the kidney, $7.1 \times 10^5$ in the spleen, and $1.3 \times 10^4$ in the brain. By contrast, viral RNA was detected from only the tonsils ($2.3 \times 10^7$ copies/g) and spleen ($1.0 \times 10^6$ copies/g) of pig G12 in Group 2 (Fig. 5B). Expectedly, no 10186-614 viral RNA was found in the sera, oral fluid, or any tissues of pigs in Groups 1 and 4.

**Gross and histological lesions**

Gross anatomic observation after euthanization on 16 dpi revealed prominent lesions of pneumonia and thymic atrophy in the organs of Group 3 pigs. The lung lesions in these pigs were characterized by dark-reddish pneumonia with congested edematous consolidation in the whole lobes (Fig. 6C, upper panel). By contrast, the lungs in most pigs of Group 2 were only slightly red compared with those in Group 1. Mean (standard deviation, SD) gross lung lesion scores were 0.8% ± 1.8% in Group 1, 12.0% ± 8.9% in Group 2, 77.2% ± 14.8% in Group 3, and 0% ± 0% in Group 4, with a significant difference between Groups 2 and 3 (Fig. 6A).

Histopathological pneumonic lesions in Group 3 were characterized by severe interstitial pneumonia with marked accumulation of proteinaceous and cell debris in alveolar spaces, marked septal infiltration with macrophages and capillary congestion in the alveolar wall (Fig. 6C, lower panel). By contrast, histopathological pneumonic lesions in Group 2 were characterized by slight to moderate histiolymphocytic infiltration in the alveolar wall. The microscopic pneumonic score (mean ± SD) in Group 2 (1.1 ± 0.3) was significantly lower than that in Group 3 (3.3 ± 0.4) (Fig. 6B).
Discussion

The results of the present study demonstrate that pigs inoculated with Japanese local strain EDRD1 are highly protected against a challenge infection with heterologous Vietnamese highly pathogenic type 2 PRRSV strain 10186-614. Viral replication, viral emission in oral fluid, clinical signs, rectal temperature, and lesion severity were significantly reduced, and average daily weight gain was significantly improved in pigs immunized with EDRD1 compared with those in non-immunized animals. Therefore, the results of the present study suggest that the immunity induced by EDRD1 inoculation strongly inhibits the replication of Vietnamese HP-PRRSV in pigs.

EDRD1 historically has been used for various studies as a Japanese standard strain because its genetically closely related variants are broadly endemic in Japan [19, 20]. Yoshii and his colleagues reported that 21 of 31 Japanese field isolates contained the same deletion pattern in the nsp2 gene [21]. To evaluate details of the amino acid deletion sites, we compared the partial nsp2 gene products of EDRD1 and 10186-614 against two historical reference strains, namely, VR-2332 and JXA1. Chinese HP-PRRSVs, including JXA1, are classified into Lineage 8/Sublineage 8.7/Subgroup 3, with 1 and 29 residues containing common deletion sites in nsp2 [22, 23]. Nucleotide sequence analysis of nsp2 of EDRD1 and comparisons among JXA1 and 10186-614 showed that the 39 amino acid deletion site of EDRD1 (VR-2332 nsp2 amino acids 509–547) was in almost the same region as the 29 amino acid deletion site of JXA1 and 10186-614 strains (VR-2332 nsp2 amino acids 538–567). The nsp2 ORF contains a conserved protease motif and predicted regions of the interaction with a matrix protein (Fig. 1), which are essential for the replication of PRRSV, but this ORF is highly tolerant of mutations in the large middle section. Furthermore, one of the two potential N-glycosylation sites (VR-2332 nsp2 amino acid 325) in that middle section was broken in the gene products of JXA1 and 10186-614 strains.

ORF5 is one of the most variable regions of the PRRSV genome, likely because it encodes the major envelope protein and can be exposed to selective pressures [18]. To elucidate the genetic distance among the two strains that we used for the present study and the two historical reference strains, we compared their ORF5 amino acid sequences. According to the latest publication for the genetic variation of type 2 PRRSV [12], four strains were classified as follows: 10186-614 and JXA1, Lineage 8/Sublineage 8.7/Subgroup 3; VR-2332, Lineage 5/Sublineage 5.1; and EDRD1, Lineage 4. ORF5 gene alignment indicated that EDRD1 is not genetically closely related to any of the other three strains of the present study (10186-614, JXA1, or VR-2332). Therefore, the sequence analysis suggests that the high cross-immunity between EDRD1 and 10186-614 was not caused by the level of the sequence identity, although it might be affected by changing the three-dimensional structure of Nsp2 due to nucleotide deletions. Although we did not deeply analyze the other regions of the PRRSV genomic sequences, considering that the aim of this analysis was to identify the genetic distances among the abovementioned viruses, these results could be representable of genome wide analysis.

We found that intranasal infection with 10186-614 quickly resulted in viremia in pigs without EDRD1 inoculation (Group 3). Although we set the experiment period to 16 dpi to minimize the pain and suffering.
of the animals challenged with 10186-614, one pig was prematurely euthanized because of severe symptoms. Viremia contributed to the distribution of the virus throughout every organ tested in the infected animals. The virus in Group 3 pigs was initially detected in serum samples at 3 dpi before peaking at 7 dpi and then remaining at high titers throughout the experimental period (Fig. 4A). Virus shedding at 7, 10, and 13 dpi was correlated with viremia (Fig. 4B); high quantities of viral RNA were detected in oral fluid collected from all animals. The virus may not be a part of a genetically homogenous population owing to the fact that we did not use a virus that was rescued from cDNA clone; however, these results are consistent with a previous report of viremia caused by this strain [24], indicating that our experimental design implements high experimental reproducibility. By contrast, viral RNAs were not detected at 3 dpi in the EDRD1-inoculated and challenged group and were significantly lower than those without EDRD1 inoculation at 7 and 13 dpi. We found that 10186-614 challenge after EDRD1 inoculation significantly reduced clinical and pathological scores and fever and restored daily weight gain to normal values in pigs compared with those without EDRD1 inoculation (Fig. 2 and Fig. 6). Notably, viral RNA in both sera and oral fluid from two of five pigs in Group 2 (pigs G8 and G10) were not detectable throughout the experiment. Furthermore, viral RNA was transiently detected from sera at 7 and 10 dpi and oral fluids at 7 dpi in pig G7, and from both sera and oral fluids at 7 dpi in pig G9 in Group 2. Although the amount of viral RNA was the lowest compared with those in Group 3 pigs, only pig G12 had continued viremia at 13 dpi and excreted the virus in oral fluid. The $2.3 \times 10^7$ and $1.0 \times 10^6$ copies/g of viral RNA were also detected from the tonsils and spleen of pig G12. Pig G12 did not generate sufficient immunity against EDRD1 inoculation because of unknown reasons; however, no viral RNA was detected from its other organs, despite it being distributed in every organ of all challenged pigs without EDRD1 inoculation (Fig. 5). Hence, the virus distributed through the bloodstream must have been captured and processed by the immune system. To elucidate the reason for the limited protection in only pig G12 against the challenge infection, we measured the EDRD1 viral quantity in the sera using EDRD1-specific PCR primers. This pig displayed almost equal EDRD1 amounts as those of the other animals in Group 2 until the 10186-614 challenge (data not shown). The S/P ratio quickly reached up to 1.0 by 10 dpi in all animals except pig G12; however, pig G12 reached this ratio at 36 dpi because of a prolonged antibody response. This animal seemed to be in good health because no clinical symptoms were recorded until the 10186-614 challenge, and the daily weight gain was almost the same as those of the other pigs in Group 2. However, neither its antibodies against whole viral particles nor the serum neutralizing antibodies was sufficient to protect pig G12 from HP-PRRSV challenge. Although we recognized that further experiments using a greater number of animals will be necessary, these results indicate that those animals that are successfully immunized by EDRD1 infection are highly protected from 10186-614 and its genetically closely related variants.

Presently, no commercially available vaccine efficiently protects against infection with HP-PRRSV. To reduce economic losses in pig production caused by Lineage 8 HP-PRRSV, some research teams have shown that presently available vaccines for non-HP-PRRSVs are partially effective in reducing symptoms and viral shedding of HP-PRRSV strains [25-27]. Similarly, we previously demonstrated that pigs immunized with the commercial type 2 PRRS MLV (modified live virus) vaccine showed significantly
reduced symptoms, viremia, and virus shedding caused by 10186-614 infection compared with those in a non-vaccinated group [24]. However, the immunity conferred by those vaccine strains could not protect the pigs from a viral infection with HP-PRRSV. In the present study, we demonstrated that pigs inoculated with EDRD1 are highly protected from 10186-614 challenge infection. Although a herd with immunity derived from Lineage 4 field isolates might show resistance against Lineage 8 HP-PRRSV, further research is necessary to test whether the same potent immunogenicity of EDRD1 against Lineage 8 HP-PRRSV can be shared with genetically closely related strains. If the unique character of EDRD1 confers such immunity, this old standard strain may be an ideal candidate for vaccine development against this economically devastating virus in the near future.

**Conclusions**

In the present study, we demonstrated that pigs are protected against acute, heterologous Vietnamese HP-PRRSV type 2 challenge by immunity against the Japanese local strain, EDRD1. Notably, two of five EDRD1-inoculated pigs showed no evidence of HP-PRRSV infection within 16 days after the challenge with this high-morbidity virus. Further research is necessary to determine whether the strong immunogenicity of EDRD1 against the economically devastating HP-PRRSV can be shared among strains that are genetically closely related.

**Methods**

**Virus**

HP-PRRSV (10186-614 strain) was isolated in 2010 from an infected pig with HP-PRRS in Vietnam using the monkey kidney cell line MARC-145 by three passages as described previously [28]. Dr. Tung and Dr. Inui kindly provided the isolated virus. The EDRD1 strain was cloned by three rounds of limiting dilution in swine alveolar macrophages, and the virus of the 17th passage was used for the animal experiments. Macrophages were obtained from pigs aged approximately 4 weeks old, as described previously [29] and were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and antibiotics (25 U/mL penicillin, 25 μg/mL streptomycin, 40 μg/mL gentamicin, 25 μg/mL neomycin, and 300 U/mL polymyxin). These isolates were stored at −80°C until use.

**Animal experiments**

Twenty-two specific pathogen free (SPF) pigs (landrace and large white crossbreds) aged 3 weeks were purchased from a closed SPF herd (Zen-Noh Livestock, Co., LTD., Tokyo, Japan), marked with an individual ear tag and randomly divided into four groups. They were negative for PRRS, pseudorabies, porcine epidemic diarrhea, transmissible gastroenteritis, atrophic rhinitis, *Mycoplasma pneumonia*, swine dysentery, salmonellosis, toxoplasma, and actinobacillosis. Pigs were also confirmed negative for antibodies to PRRSV before the experiment using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (PRRS X3 Ab Test; IDEXX Laboratories, Westbrook, ME, USA). Group 1 (N = 5; pigs G1–G5) and Group 2 (N = 6; pigs G7–G12. G11 was excluded from subsequent experiments at 12 days after EDRD1 inoculation due to the accidental death.) were inoculated with 1 mL nasal spray containing strain EDRD1 at a median tissue culture infectious dose (TCID\textsubscript{50}) of 1 × 10\textsuperscript{5}. After 26 days, Groups 2 and 3 were challenged with 1 mL nasal spray containing 1 × 10\textsuperscript{5} TCID\textsubscript{50} of strain 10186-614 (N = 6; pigs G13–G18). The remaining five pigs were nasally administered 1 mL medium on the same schedule as the other groups and were used as uninfected controls (Group 4; pigs G19–G23). The sample size (N = 6) was determined as the 4 animals for the minimum number of the statistical analysis and an additional 2 animals because of a predicted 10–20% mortality rate according to the previous report [24].

The pigs of each group were housed in a separate room of the animal facility where they received a commercial diet and were monitored for rectal temperature, clinical signs, and body weight throughout the experimental period. The rooms were cleaned daily by qualified personnel. All pigs were euthanized and necropsied at 16 dpi with 10186-614 for pathologic and virologic assays except pig G17, which was euthanized at 12 dpi at a humane endpoint to release the animal from pain and suffering. At the end of euthanasia, the piglets were anaesthetized intramuscularly with a mixture of 20 mg/kg ketamine hydrochloride (Ketalar; Daiichi Sankyo Propharma Co., Tokyo, Japan) and 0.3 mg/kg xylazine (Selactal; Bayer Medical Co., Wuppertal, Germany) prior to euthanization by the intravenous administration of a barbiturate (Somnopentyl, Kyoritsu Selyaku, Tokyo, Japan) according to the manufacturer's instruction. Then the piglets were humanely bled to death. All the data set collected from live animals were used for subsequent analysis. To monitor the viral RNA, serum was collected at −26, −22, −19, −15, −11, −7, −4, 0, 3, 7, 10, and 13 dpi, and oral fluids were collected at 0, 3, 7, 10, and 13 dpi. Oral fluid samples collected using Salivette Cotton (Sarstedt, Nümbrecht, Germany), were immediately centrifuged, and the supernatant was stored at −80°C until use. Blood and oral fluid were collected from the animals in a random order each time. Animal experiments were performed according to regulations and guidelines of the Animal Ethics Committee of the National Institute of Animal Health (approval number 13-047). To conduct the acts of randomization and blinding appropriately, blood sampling was conducted by various researchers barring the 1st and 2nd authors; viral and pathological examination were performed separately by the 1st and 2nd authors.

**RT-qPCR**

During necropsy, lung, liver, tonsil, kidney, spleen, and brain tissues were collected for quantification of viral RNA. Viral RNA from serum and oral fluid was extracted using a QIAamp Viral RNA Mini kit (Qiagen, Tokyo, Japan); tissue viral RNA was extracted using a Qiagen RNeasy Mini kit (Qiagen). Viral RNA extracts were then used as templates for one-step reverse transcriptase quantitative-polymerase chain reaction (RT-qPCR) with a One-Step SYBR® PrimeScript\textsuperscript{TM} RT-PCR kit II (Perfect Real-Time; Takara Bio Inc., Shiga, Japan). RNA extraction and RT-qPCR assay were conducted according to the manufacturer’s instructions. To detect the two types of viral RNAs separately, two pairs of PCR primers were designed based on the nsp2 gene of 10186-614 (forward, 5’-AACTGTGACAACAACGC-3’, and reverse, 5’-
CGATGATGGCTTGAGCTGAGT-3') and EDRD1 (forward, 5’-ATCCCTGTGCCCACC-3’, and reverse, 5’-GTCGATAATGGCTTGAGCTGAAC-3’). For the standard curve, positive control DNA was generated for the synthetic gene 10186-614 (partial, 267 bp) and EDRD1 nsp2 (partial, 317 bp) synthesized from forward to reverse primers by GeneArt® Strings DNA Fragments (Thermo Fisher Scientific, Waltham, MA, USA). A linear standard curve was generated for each RT-qPCR reaction using serial dilutions of each synthetic DNA fragment. The Cₜ values are valid only between the minimum and maximum values obtained using the standard RNA. Fluorescence data were analyzed using PE 7500 Sequence Detection System Software Version 1 (Thermo Fisher Scientific).

Pathological examinations

The scoring system used for visible pneumonia and histopathologic pneumonic lesions followed a previous paper [30] with modification to match the characteristics of lesions from an experimental infection with HP-PRRSV. A visual examination and microscopic examination were conducted according to the methods presented in our previous study (24). No significant pathogens were isolated from the tissues collected from pigs in any of the groups at necropsy.

Statistical analysis

Body temperature and viral RNA values were analyzed using an unpaired t-test. Microscopic pneumonia scores were analyzed using the Mann–Whitney U-test with the “EZR” package in the R statistical environment (Foundation for Statistical Computing). A P value of <0.05 was considered statistically significant.

Abbreviations

**DNA:** deoxyribonucleic acid

**dpi:** days post-infection

**ELISA:** enzyme-linked immunosorbent assay

**GP:** glycoprotein

**HP-PRRSV:** highly pathogenic porcine reproductive and respiratory syndrome virus

**MLV:** modified live virus

**N.D.:** not detected

**Nsp:** nonstructural protein
ORF: open reading frame

PRRS: porcine reproductive and respiratory syndrome

PRRSV: porcine reproductive and respiratory syndrome virus

RT-qPCR: reverse transcriptase-quantitative polymerase chain reaction

RNA: ribonucleic acid

SAM: swine alveolar macrophage

SD: standard deviation

SE: standard error

S/P ratio: sample-to-positive ratio

SPF: specific pathogen free

TCID$_{50}$: median tissue culture infectious dose

**Declarations**

**Ethics approval and consent to participate**

Animal experiments were performed according to regulations and guidelines of the Animal Ethics Committee of the National Institute of Animal Health (approval number 13-047).

**Consent for publication**

Not applicable.

**Availability of data and materials**

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.
Competing interests

We declare no commercial or associated interests that would represent a conflict of interest in connection with the work submitted.

Funding

The financial support provided by JSPS KAKENHI Grant Number 24780301. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors contributions

Conception and design of the study: HI and KK; Acquisition of data: HI and KK; Drafting of the article: HI, KK, and TS; Revision of the manuscript and final approval: all.

Acknowledgments

The authors thank the staff of the NIAH for animal handling and technical assistance, and we are grateful to Dr. Nguyen Tung (International cooperation and communication section, Department of Animal Health, MARD, Hanoi, Vietnam) and Dr. Kenjiro Inui (National Center for Veterinary Diagnosis, Hanoi, Vietnam) for giving us the isolated virus.

References

1. Kuhn JH, Lauck M, Bailey AL, Shchetinin AM, Vishnevskaya TV, Bao Y, Ng TF, LeBreton M, Schneider BS, Gillis A et al: Reorganization and expansion of the nidoviral family Arteriviridae. Arch Virol 2016, 161(3):755-768.
2. Wensvoort G, Terpstra C, Pol JM, ter Laak EA, Bloemraad M, de Kluyver EP, Kragten C, van Buiten L, den Besten A, Wagenaar F et al: Mystery swine disease in The Netherlands: the isolation of Lelystad
virus. Vet Q 1991, 13(3):121-130.

3. Collins JE, Benfield DA, Christianson WT, Harris L, Hennings JC, Shaw DP, Goyal SM, McCullough S, Morrison RB, Joo HS et al: Isolation of swine infertility and respiratory syndrome virus (isolate ATCC VR-2332) in North America and experimental reproduction of the disease in gnotobiotic pigs. J Vet Diagn Invest 1992, 4(2):117-126.

4. Murtaugh MP, Elam MR, Kakach LT: Comparison of the structural protein coding sequences of the VR-2332 and Lelystad virus strains of the PRRS virus. Arch Virol 1995, 140(8):1451-1460.

5. Tian K, Yu X, Zhao T, Feng Y, Cao Z, Wang C, Hu Y, Chen X, Hu D, Tian X et al: Emergence of fatal PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique hallmark. PLoS One 2007, 2(6):e526.

6. Karnyychuk UU, Geldhof M, Vanhee M, Van Doorselaere J, Saveleva TA, Nauwynck HJ: Pathogenesis and antigenic characterization of a new East European subtype 3 porcine reproductive and respiratory syndrome virus isolate. BMC Vet Res 2010, 6:30.

7. Zhou L, Yang H: Porcine reproductive and respiratory syndrome in China. Virus Res 2010, 154(1-2):31-37.

8. Feng Y, Zhao T, Nguyen T, Inui K, Ma Y, Nguyen TH, Nguyen VC, Liu D, Bui QA, To LT et al: Porcine respiratory and reproductive syndrome virus variants, Vietnam and China, 2007. Emerg Infect Dis 2008, 14(11):1774-1776.

9. Nilubol D, Tripipat T, Hoonsuwan T, Tipsombatboon P, Piriyapongsa J: Dynamics and evolution of porcine reproductive and respiratory syndrome virus (PRRSV) ORF5 following modified live PRRSV vaccination in a PRRSV-infected herd. Arch Virol 2014, 159(1):17-27.

10. Shimizu M, Yamada S, Murakami Y, Morozumi T, Kobayashi H, Mitani K, Ito N, Kubo M, Kimura K, Kobayashi M et al: Isolation of porcine reproductive and respiratory syndrome (PRRS) virus from Heko-Heko disease of pigs. J Vet Med Sci 1994, 56(2):389-391.

11. Murakami Y, Kato A, Tsuda T, Morozumi T, Miura Y, Sugimura T: Isolation and serological characterization of porcine reproductive and respiratory syndrome (PRRS) viruses from pigs with reproductive and respiratory disorders in Japan. J Vet Med Sci 1994, 56(5):891-894.

12. Guo Z, Chen XX, Li R, Qiao S, Zhang G: The prevalent status and genetic diversity of porcine reproductive and respiratory syndrome virus in China: a molecular epidemiological perspective. Virol J 2018, 15(1):2.

13. Allende R, Lewis TL, Lu Z, Rock DL, Kutish GF, Ali A, Doster AR, Osorio FA: North American and European porcine reproductive and respiratory syndrome viruses differ in nonstructural protein coding regions. J Gen Virol 1999, 80(Pt 2):307-315.

14. Han J, Wang Y, Faaberg KS: Complete genome analysis of RFLP 184 isolates of porcine reproductive and respiratory syndrome virus. Virus Res 2006, 122(1-2):175-182.

15. Leng C, Zhang W, Zhang H, Kan Y, Yao L, Zhai H, Li M, Li Z, Liu C, An T et al: ORF1a of highly pathogenic PRRS attenuated vaccine virus plays a key role in neutralizing antibody induction in piglets and virus neutralization in vitro. Virol J 2017, 14(1):159.
16. Kim W, Lee DS, Johnson W, Roof M, Cha SH, Yoon KJ: Effect of genotypic and biotypic differences among PRRS viruses on the serologic assessment of pigs for virus infection. Vet Microbiol 2007, 123(1-3):1-14.

17. Mengeling WL, Lager KM, Vorwald AC, Koehler KJ: Strain specificity of the immune response of pigs following vaccination with various strains of porcine reproductive and respiratory syndrome virus. Vet Microbiol 2003, 93(1):13-24.

18. Kapur V, Elam MR, Pawlovich TM, Murtaugh MP: Genetic variation in porcine reproductive and respiratory syndrome virus isolates in the midwestern United States. J Gen Virol 1996, 77(Pt 6):1271-1276.

19. Iseki H, Morozumi T, Takagi M, Kawashima K, Shibahara T, Uenishi H, Tsunemitsu H: Genomic sequence and virulence evaluation of MN184A-like porcine reproductive and respiratory syndrome virus in Japan. Microbiol Immunol 2016, 60(12):824-834.

20. Yoshii M, Kaku Y, Murakami Y, Shimizu M, Kato K, Ikeda H: Genetic variation and geographic distribution of porcine reproductive and respiratory syndrome virus in Japan. Arch Virol 2005, 150(11):2313-2324.

21. Iseki H, Takagi M, Miyazaki A, Katsuda K, Mikami O, Tsunemitsu H: Genetic analysis of ORF5 in porcine reproductive and respiratory syndrome virus in Japan. Microbiol Immunol 2011, 55(3):211-216.

22. Wu J, Li J, Tian F, Ren S, Yu M, Chen J, Lan Z, Zhang X, Yoo D, Wang J: Genetic variation and pathogenicity of highly virulent porcine reproductive and respiratory syndrome virus emerging in China. Arch Virol 2009, 154(10):1589-1597.

23. An TQ, Zhou YJ, Liu GQ, Tian ZJ, Li J, Qiu HJ, Tong GZ: Genetic diversity and phylogenetic analysis of glycoprotein 5 of PRRSV isolates in mainland China from 1996 to 2006: coexistence of two NA-subgenotypes with great diversity. Vet Microbiol 2007, 123(1-3):43-52.

24. Iseki H, Kawashima K, Tung N, Inui K, Ikezawa M, Shibahara T, Yamakawa M: Efficacy of Type 2 porcine reproductive and respiratory syndrome virus (PRRSV) vaccine against the 2010 isolate of Vietnamese highly pathogenic PRRSV challenge in pigs. J Vet Med Sci 2017, 79(4):765-773.

25. Sattler T, Pikalo J, Wodak E, Schmoll F: Performance of ELISAs for detection of antibodies against porcine respiratory and reproductive syndrome virus in serum of pigs after PRRSV type 2 live vaccination and challenge. Porcine Health Manag 2015, 1:19.

26. Do DT, Nguyen TT, Nguyen NTH, Nguyen MHP, Le HT, Nguyen NTT, Nguyen NTP, Chae C, Mah CK: The efficacy and performance impact of Fostera PRRS in a Vietnamese commercial pig farm naturally challenged by a highly pathogenic PRRS virus. Trop Anim Health Prod 2020, 52(4):1725-1732.

27. Lager KM, Schlink SN, Brockmeier SL, Miller LC, Henningson JN, Kappes MA, Kehrli ME, Loving CL, Guo B, Swenson SL et al: Efficacy of Type 2 PRRSV vaccine against Chinese and Vietnamese HP-PRRSV challenge in pigs. Vaccine 2014, 32(48):6457-6462.

28. Kim HS, Kwang J, Yoon IJ, Joo HS, Frey ML: Enhanced replication of porcine reproductive and respiratory syndrome (PRRS) virus in a homogeneous subpopulation of MA-104 cell line. Arch Virol
1993, 133(3-4):477-483.

29. Mengeling WL, Lager KM, Vorwald AC: Diagnosis of porcine reproductive and respiratory syndrome. J Vet Diagn Invest 1995, 7(1):3-16.

30. Halbur PG, Paul PS, Frey ML, Landgraf J, Eernisse K, Meng XJ, Lum MA, Andrews JJ, Rathje JA: Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Vet Pathol 1995, 32(6):648-660.

31. Hulo N, Bairoch A, Bulliard V, Cerutti L, De Castro E, Langendijk-Genevaux PS, Pagni M, Sigrist CJ: The PROSITE database. Nucleic Acids Res 2006, 34(Database issue):D227-230.

Tables

Table 1 Pairwise comparison of the amino acid sequences of ORF5

| Virus     | U87392 | EF112445 | LC569874 | AB288356 |
|-----------|--------|----------|----------|----------|
| VR-2332   | 100.0  | 87.9     | 89.5     | 89.4     |
| JXA1      | 87.9   | 100.0    | 97.0     | 88.9     |
| 10186-614 | 89.5   | 97.0     | 100.0    | 89.9     |
| EDRD1     | 89.4   | 88.9     | 89.9     | 100.0    |